PRA Health Sciences (PRAH) Tops Q2 EPS by 7c, Raises FY15 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PRAH Hot Sheet
Join SI Premium – FREE
PRA Health Sciences (NASDAQ: PRAH) reported Q2 EPS of $0.47, $0.07 better than the analyst estimate of $0.40. Revenue for the quarter came in at $336.5 million versus the consensus estimate of $336.74 million.
PRA Health Sciences sees FY2015 EPS of $1.75-$1.85, versus prior guidance of $1.62-$1.72 and the consensus of $1.67. PRA Health Sciences sees FY2015 revenue of $1.34-1.39 billion, versus the consensus of $1.37 billion.
For earnings history and earnings-related data on PRA Health Sciences (PRAH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Reynolds Consumer Products Inc. (REYN) Tops Q3 EPS by 1c, Beats on Revenue; Offers FY26 EPS Guidance
- Twin Disc (TWIN) Tops Q1 EPS by 13c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
